Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Y-mAbs Therapeutics, Inc.

8.61
0.0000
Volume:- -
Turnover:6.54M
Market Cap:391.22M
PE:-17.40
High:8.61
Open:8.61
Low:8.61
Close:8.61
52wk High:16.11
52wk Low:3.55
Shares:45.44M
Float Shares:18.59M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4948
EPS(LYR):-0.6692
ROE:-24.31%
ROA:-8.67%
PB:4.47
PE(LYR):-12.87

Loading ...

OverviewCompanyNewsFilings

Company Profile

Company Name:
Y-mAbs Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Website:
http://www.ymabs.com
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.